[An Effective Treatment of Relapsed Leiomyosarcoma with Fourth-Line Trabectedin].

Abstract

A 56-year-old women underwent retroperitoneal leiomyosarcoma resection in December 2011. In July 2015, CT showed multiple liver metastases, and she received first-line chemotherapy treatment with doxorubicin. After 2 courses of doxorubicin, her performance status deteriorated; therefore, she was treated with pazopanib as second-line chemotherapy. PFS with pazopanib was 5 months and that with eribulin was 2.5 months. She was then treated with trabectedin as fourth-line chemotherapy from July 2016. The liver metastases reduced, and the disease was controlled for 1 year and 6 months following administration of trabectedin. We continue to treat this patient with trabectedin, and no serious side effects have been observed.

• Authors: Yumi Nozaki, Shigeo Yamaguchi, Tatsuya Takagi, Shunsuke Kato
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 46 Issue 2 Pg. 275-277 (Feb 2019) ISSN: 0385-0684 [Print] Japan
• PMID: 30914533 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Dioxoles
• Tetrahydroisoquinolines
• Trabectedin

Topics

• Antineoplastic Agents, Alkylating (therapeutic use)
• Dioxoles
• Female
• Humans
• Leiomyosarcoma (drug therapy)
• Middle Aged
• Tetrahydroisoquinolines
• Trabectedin (therapeutic use)
• Treatment Outcome